Facial Implants in India and UAE | Complete Patient Guide

• IDEAL CANDIDATES (AESTHETIC):

• Adults aged 18 or older with fully developed craniofacial skeleton (skeletal maturity confirmed on lateral cephalometric radiograph)

• Patients with chin projection deficit (Holdaway angle <9°, or soft-tissue pogonion more than 2 mm posterior to a vertical dropped from subnasale)

• Malar hypoplasia with a negative vector orbit (globe anterior to the inferior orbital rim on lateral view)

• Mandibular angle deficiency resulting in a narrow or weak-appearing lower face

• Pyriform aperture and premaxillary deficiency causing perioral flattening or premature lower-third ageing

• Patients who have plateaued with injectable fillers and seek a permanent, structurally stable solution

• RECONSTRUCTIVE / MEDICAL CANDIDATES:

• Post-traumatic facial skeletal deficiency following zygomaticomaxillary complex (ZMC) fractures with inadequate primary reduction

• Post-oncologic resection reconstruction where vascularised free-flap reconstruction is not indicated

• Congenital conditions: hemifacial microsomia (Pruzansky-Kaban Type I), Treacher Collins syndrome, Pierre Robin sequence with residual mandibular hypoplasia

• Gender-affirming facial surgery (feminisation or masculinisation) requiring skeletal-level augmentation

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• Standardised facial photographs (frontal, lateral, oblique, basal views) and digital morphing for surgical simulation

• Lateral cephalometric radiograph (for chin/jaw planning, Steiner and Holdaway analysis)

• CBCT or multislice CT of the facial skeleton (mandatory for PSI planning, trauma cases, or complex multi-site augmentation)

• Routine bloods: CBC, coagulation profile (PT/INR/aPTT), metabolic panel, HbA1c (diabetic patients), thyroid function if indicated

• Dental panoramic radiograph (OPG) to assess tooth root proximity to intraoral incision sites

• Allergy testing or implant material sensitivity assessment if prior silicone reactions are reported

• RELATIVE CONTRAINDICATIONS:

• Active cutaneous or dental infection in the operative field

• Uncontrolled type 2 diabetes mellitus (HbA1c >8.0% — elevated infection and wound-healing risk)

• Active autoimmune connective tissue disease (e.g., systemic lupus erythematosus, scleroderma)

• Significant bone resorption at implant site insufficient to anchor hardware

• Bleeding diatheses or mandatory anticoagulation that cannot be safely bridged

• Body dysmorphic disorder (BDD) — psychiatric screening with a validated instrument (e.g., BDD-YBOCS) is recommended prior to elective aesthetic surgery

• Pregnancy or active breast-feeding

• Skeletally immature patients (age <17 in females, <18 in males) except in severe reconstructive indications

STANDARD ALLOPLASTIC IMPLANT AUGMENTATION (PRIMARY TECHNIQUE)

This remains the gold-standard approach for elective augmentation. Solid silicone implants (Shore A hardness 20–30) are placed in a subperiosteal pocket through hidden intraoral or strategically placed cutaneous incisions. The implant is selected from a sizing system (e.g., Implantech, Stryker, or Establishment Labs catalogues) using pre-operative cephalometric measurements. Fixation is typically achieved by periosteal closure alone for chin implants, or titanium microscrew fixation (1.5 mm system) for malar and mandibular angle sites where shear forces are higher. Operative time per site: 45–90 minutes. This technique is suitable for primary, single-site augmentation with moderate volumetric requirements.

PATIENT-SPECIFIC IMPLANTS (PSI) VIA CAD/CAM TECHNOLOGY

For patients with complex asymmetry, significant skeletal deficiency, post-traumatic deformity, or those requiring multi-site augmentation, PSI are fabricated using the patient's own CT data. The surgical plan is executed digitally (Materialise ProPlan CMF, DePuy Synthes ProFace, or KLS Martin CARES system), and the implant is milled from medical-grade PEEK (polyether ether ketone) or cast in high-consistency silicone elastomer. Surgical cutting guides or positioning guides, also 3D-printed from the same dataset, ensure sub-millimetre implant placement accuracy intraoperatively. PSI virtually eliminates the need for intraoperative implant modification (bending, trimming), reduces operative time in experienced centres, and yields superior symmetry outcomes compared to off-the-shelf implants. Fabrication lead time is typically 3–6 weeks, which must be incorporated into treatment planning timelines.

PORUS POLYETHYLENE (MEDPOR) IMPLANTS

High-density porous polyethylene (HDPE) with an interconnected pore network of 100–250 microns allows fibrovascular tissue ingrowth, anchoring the implant biologically over 6–12 weeks post-implantation. This property makes Medpor advantageous at the orbital rim, malar eminence, and pyriform aperture, where long-term stability without screw fixation is desired and where smooth silicone may migrate. The trade-off is greater intraoperative technical difficulty during implant contouring and the practical irreversibility of explantation compared to smooth silicone.

COMBINED SKELETAL AND SOFT-TISSUE PROCEDURES

Facial implant surgery is frequently combined with:

• Rhinoplasty (for facial proportion harmonisation — the Gonzalez-Ulloa aesthetic plane guides combined chin-nose surgery)

• Lower blepharoplasty with malar implant placement (shared incision, addresses negative vector simultaneously)

• Facelift (rhytidectomy) — malar implants placed through facelift incisions restore midface volume, reducing the need for deep-plane dissection

• Fat grafting (structural fat grafting, SFG) to blend implant margins and augment soft-tissue envelope

• Orthognathic surgery (Le Fort I osteotomy, BSSO) when skeletal discrepancies exceed the corrective range of alloplastic augmentation alone (typically >8–10 mm chin deficiency)

ENDOSCOPIC-ASSISTED PLACEMENT

For malar and midface implants, endoscopic-assisted subperiosteal dissection (via temporal or upper gingivobuccal ports) minimises incision length and improves visualisation in the dissection plane. This approach is particularly valuable in male patients with thick, vascularised periosteum and in revision cases where scar tissue obscures anatomical landmarks.

REVISION AND EXPLANTATION

Revision surgery addresses implant malposition, asymmetry, infection, or patient-requested size change. Revision rates for chin implants in high-volume centres are reported at 4–8%. Explantation is performed under the same anaesthetic approach, and in cases of silicone implant removal, the fibrous capsule is either left in situ or excised (capsulectomy) depending on capsule characteristics.

PRE-OPERATIVE PHASE (4–8 WEEKS BEFORE SURGERY)

• Step 1 — Virtual Consultation with GAF Healthcare: Standardised photographic submission (7-view facial series), completion of medical history form, and video consultation with the assigned surgeon. Digital morphing and simulation images shared with the patient within 48–72 hours.

• Step 2 — Diagnostic Workup: CBCT or CT facial skeleton, cephalometric radiograph, OPG, and blood panel completed at a GAF-partnered diagnostic centre. If PSI is selected, CT DICOM data is submitted to the implant manufacturer; allow 3–6 weeks for fabrication.

• Step 3 — Anaesthesia Assessment: Online pre-anaesthesia questionnaire reviewed by the anaesthesiologist. Patients on anticoagulants, antiplatelets, or NSAIDs must cease medication 7–14 days pre-operatively per haematology guidance.

• Step 4 — Travel and Visa Arrangement: GAF Healthcare coordinates e-Medical Visa application (India) or tourist/medical entry visa (UAE). Confirmed surgical date provided; patient books flights to arrive 2–3 days before surgery for final pre-operative review.

• Step 5 — Pre-operative Clinic Visit (Day -1 or Day of Admission): Final surgeon examination, implant sizing confirmation (trial sizers placed over skin surface), written informed consent, anaesthesia review, pre-operative antibiotics prescription (typically amoxicillin-clavulanate or clindamycin for penicillin-allergic patients), and chlorhexidine oral rinse regimen initiated.

INTRAOPERATIVE PHASE (Day 0)

• Anaesthesia: General endotracheal anaesthesia (GETA) is standard for multi-site or combined procedures. Sedation with local anaesthesia (MAC — Monitored Anaesthesia Care) is an option for isolated single-site chin augmentation in appropriate patients.

• Incision and Dissection: Intraoral or external incisions as planned. Subperiosteal dissection to the implant pocket using periosteal elevators (Freer, Langenbeck). Haemostasis confirmed before implant insertion.

• Implant Placement and Fixation: Trial sizer confirmed, final implant inserted, symmetry assessed clinically and with intraoperative photography. Titanium microscrews placed if indicated.

• Closure: Layered closure of periosteum and mucosa with 3-0 or 4-0 absorbable sutures (Vicryl/Monocryl). External incisions closed with 5-0 nylon or tissue adhesive.

• Duration: 1–2 hours for single-site; 3–5 hours for multi-site or combined procedures.

POST-OPERATIVE — ACUTE PHASE (Days 1–7)

• Day 1: Recovery in post-anaesthesia care unit (PACU). Ice packs applied. Liquid diet initiated. IV antibiotics continued for 24 hours, then transitioned to oral. Pain managed with paracetamol + NSAIDs or tramadol as required. Chin strap or compression garment applied for mandibular and malar sites.

• Days 2–3: Discharge from hospital (or day-surgery discharge same evening for uncomplicated single-site). Significant swelling and bruising expected — this is physiologically normal and does not indicate complication. Swelling peaks at 48–72 hours.

• Days 4–7: Soft diet maintained. Oral hygiene with chlorhexidine rinse (intraoral incisions). Suture check if external incisions used. Activity restricted to gentle walking; no bending, straining, or contact.

POST-OPERATIVE — INTERMEDIATE PHASE (Weeks 1–3)

• Week 1: Outpatient review with surgeon. Intraoral sutures begin dissolving. Visible bruising fades. Implant position assessed clinically. Patient remains in destination country.

• Week 2: Approximately 60–70% of oedema has resolved. Light social activities resumed. Compression garment continued at night. Surgeon confirms fit-to-fly status — typically cleared at Day 14 minimum for short-haul, Day 21 recommended for long-haul international flights.

• Week 3: Most patients achieve social presentability. Return to sedentary and light work. Intraoral wounds fully epithelialised.

POST-OPERATIVE — RECOVERY AND FINAL RESULT PHASE (Weeks 4–16)

• Week 4–6: Return to non-contact exercise. External scar maturation ongoing. Sensation returning to the mental nerve distribution (chin augmentation patients commonly experience temporary paraesthesia which resolves over 6–12 weeks).

• Month 3: Approximately 90% of final result visible. Implant fully integrated with surrounding fibrous capsule.

• Month 4–6: Complete resolution of residual oedema. Final aesthetic result assessed with post-operative standardised photography compared to pre-operative baseline. Revision decision, if any, deferred to this timepoint.

• Month 12: Annual follow-up recommended; imaging (ultrasound or CT) only if clinical concern arises.